| Indication |
For the management of increased muscle tone associated with spasticity |
| Pharmacodynamics |
Tizanidine is a short-acting drug for the management of
spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and
presumably reduces spasticity by increasing presynaptic inhibition of
motor neurons. In animal models, tizanidine has no direct effect on
skeletal muscle fibers or the neuromuscular junction, and no major
effect on monosynaptic spinal reflexes. The effects of tizanidine are
greatest on polysynaptic pathways. The overall effect of these actions
is thought to reduce facilitation of spinal motor neurons. |
| Mechanism of action |
Tizanidine reduces spasticity by increasing presynaptic inhibition
of motor neurons through agonist action at a2-adrenergic receptor
sites. |
| Absorption |
Not Available |
| Volume of distribution |
|
| Protein binding |
30% |
| Metabolism |
Not Available |
| Route of elimination |
Approximately 95% of an administered dose is metabolized. |
| Half life |
2.5 hours |
| Clearance |
Not Available |
| Toxicity |
Not Available |
